Navinci Diagnostics

Navinci Diagnostics is a private, Uppsala-based company commercializing its proprietary Naveni® in situ proximity ligation technology for the spatial proteomics research market. The company offers flexible and target-specific assay kits, as well as services, to enable researchers to visualize and quantify protein interactions and modifications directly in cultured cells and tissue samples. Operating in the diagnostics and oncology sectors, Navinci is positioned as a tools and services provider in the rapidly growing field of spatial biology, catering primarily to academic and biopharma research customers. Its technology aims to bridge a gap in functional proteomic analysis by providing molecular-level spatial information that traditional methods lack.

Proprietary Naveni® in situ proximity ligation assay (isPLA) technology. It uses oligonucleotide-conjugated secondary antibodies (Navenibodies) that, upon binding to primary antibodies in close proximity, enable a rolling circle amplification to generate a localized fluorescent signal for detecting protein-protein interactions, post-translational modifications, and specific protein localization in tissue and cell samples.

Navinci competes in the spatial proteomics segment against companies offering multiplexed immunofluorescence platforms (e.g., Akoya Biosciences, Lunaphore) and other proximity-based detection technologies. Its primary differentiation is the specific ability to detect true protein-protein interactions (<40nm) rather than simple co-localization. It faces competition from broader life science tools companies that may have greater commercial reach and resources.